Literature DB >> 22013731

Endothelial dysfunction as assessed by flow-mediated dilation in patients with cardiac syndrome X: role of inflammation.

P Tondi1, A Santoliquido, A Di Giorgio, A Sestito, G A Sgueglia, R Flore, G Careri, G Pinnacchio, G A Lanza, F Crea.   

Abstract

BACKGROUND: Endothelial dysfunction, reduced coronary flow reserve and increased markers of inflammation are detectable in cardiac syndrome X (CSX). In this study we investigated the relation between inflammation and systemic endothelial function in CSX patients.
METHODS: We studied 42 CSX patients (55 +/- 6 years, 14 men) and 20 healthy subjects (52 +/- 7 years, 9 men). Systemic endothelial function was assessed by flow-mediated dilation (FMD) of the brachial artery after 5-minute of forearm cuff inflation. Serum C-reactive protein (CRP) was measured by a high-sensitivity method.
RESULTS: FMD was significantly lower in CSX patients compared to controls (4.8 +/- 4.4 vs. 13.7 +/- 4%, p < 0.001), whereas CRP levels were higher in CSX patients than in controls (2.7 +/- 2.4 vs. 0.7 +/- 0.4 mg/L, p = 0.001). In CSX patients FMD showed a significant inverse correlation with CRP levels, even after adjustment for potentially confounding variables (r = -0.34, p = 0.006).
CONCLUSION: An impaired FMD is detectable in CSX patients, suggesting a generalized abnormality in vascular function. Subclinical inflammation se is to play a significant role in the impairment of endothelium-dependent vasodilator function of these patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22013731

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  11 in total

1.  Elevations in C-reactive protein and endothelin-1 system activity in humans.

Authors:  Caitlin A Dow; Danielle L Templeton; Grace M Lincenberg; Jared J Greiner; Brian L Stauffer; Christopher A DeSouza
Journal:  Life Sci       Date:  2015-12-11       Impact factor: 5.037

Review 2.  Targeting the dominant mechanism of coronary microvascular dysfunction with intracoronary physiology tests.

Authors:  Hernán Mejía-Rentería; Nina van der Hoeven; Tim P van de Hoef; Julius Heemelaar; Nicola Ryan; Amir Lerman; Niels van Royen; Javier Escaned
Journal:  Int J Cardiovasc Imaging       Date:  2017-05-13       Impact factor: 2.357

Review 3.  Etiopathogenesis of microvascular angina: caveats in our knowledge.

Authors:  S R Mittal
Journal:  Indian Heart J       Date:  2014-11-04

4.  Association between microvascular angina and erectile dsyfunction.

Authors:  S Demirkol; S Balta; U Kucuk; T Celik; Z Arslan; H Olgun Kucuk; M Unlu; U Cagdas Yuksel; S Samedli; M Yokusoglu; A Iyisoy; H Kursaklioglu
Journal:  Int J Impot Res       Date:  2013-12-19       Impact factor: 2.896

Review 5.  Unmet Needs in the Pathogenesis and Treatment of Cardiovascular Comorbidities in Chronic Inflammatory Diseases.

Authors:  Cristina Panico; Gianluigi Condorelli
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

6.  Pretreatment with Shenmai Injection Protects against Coronary Microvascular Dysfunction.

Authors:  Zhaohai Zheng; Zhangjie Yu; Buyun Xu; Yan Zhou; Yangbo Xing; Qingsong Li; Weiliang Tang; Fang Peng
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-09       Impact factor: 2.650

Review 7.  Coronary microvascular dysfunction: an update.

Authors:  Filippo Crea; Paolo G Camici; Cathleen Noel Bairey Merz
Journal:  Eur Heart J       Date:  2013-12-23       Impact factor: 29.983

8.  The association of brachial flow-mediated dilation and high-sensitivity C-reactive protein levels with Duke treadmill score in patients with suspected microvascular angina.

Authors:  Chufan Luo; Yi Li; Donghong Liu; Chengheng Hu; Zhimin Du
Journal:  Exp Clin Cardiol       Date:  2012

9.  Inflammation, coronary flow reserve, and microvascular dysfunction: moving beyond cardiac syndrome X.

Authors:  Viviany R Taqueti; Paul M Ridker
Journal:  JACC Cardiovasc Imaging       Date:  2013-06

10.  The relationship between neutrophil-to-lymphocyte ratio and albuminuria in type 2 diabetic patients: a pilot study.

Authors:  Cüneyt Kahraman; Nilüfer Kuzeyli Kahraman; Bekir Aras; Süleyman Coşgun; Erim Gülcan
Journal:  Arch Med Sci       Date:  2016-05-18       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.